CN116368136B - Egfr抑制剂 - Google Patents

Egfr抑制剂

Info

Publication number
CN116368136B
CN116368136B CN202180061165.8A CN202180061165A CN116368136B CN 116368136 B CN116368136 B CN 116368136B CN 202180061165 A CN202180061165 A CN 202180061165A CN 116368136 B CN116368136 B CN 116368136B
Authority
CN
China
Prior art keywords
group
compound
leu
egfr
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180061165.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN116368136A (zh
Inventor
小口憩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of CN116368136A publication Critical patent/CN116368136A/zh
Application granted granted Critical
Publication of CN116368136B publication Critical patent/CN116368136B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202180061165.8A 2020-07-15 2021-07-14 Egfr抑制剂 Active CN116368136B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-121525 2020-07-15
JP2020121525 2020-07-15
PCT/JP2021/026461 WO2022014639A1 (ja) 2020-07-15 2021-07-14 Ｅｇｆｒ阻害剤

Publications (2)

Publication Number Publication Date
CN116368136A CN116368136A (zh) 2023-06-30
CN116368136B true CN116368136B (zh) 2025-09-05

Family

ID=79554696

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180061165.8A Active CN116368136B (zh) 2020-07-15 2021-07-14 Egfr抑制剂

Country Status (12)

Country Link
US (1) US20230285397A1 (enExample)
EP (1) EP4197538A4 (enExample)
JP (1) JP7495983B2 (enExample)
KR (1) KR102873219B1 (enExample)
CN (1) CN116368136B (enExample)
AU (1) AU2021309779B2 (enExample)
BR (1) BR112023000770A2 (enExample)
CA (1) CA3189460A1 (enExample)
MX (1) MX2023000693A (enExample)
PH (1) PH12023550119A1 (enExample)
TW (1) TW202216152A (enExample)
WO (1) WO2022014639A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230255972A1 (en) * 2020-07-15 2023-08-17 Taiho Pharmaceutical Co., Ltd. Pyrimidine compound-containing combination to be used in tumor treatment
JP7391226B2 (ja) * 2020-07-15 2023-12-04 大鵬薬品工業株式会社 ピリミジン化合物の結晶
JP2024520461A (ja) * 2021-05-24 2024-05-24 大鵬薬品工業株式会社 Ｅｇｆｒ及び／又はｈｅｒ２に異常を有するがんを有する対象の治療方法
KR20250164828A (ko) 2023-03-30 2025-11-25 레볼루션 메디슨즈, 인크. Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020145374A1 (ja) * 2019-01-11 2020-07-16 大鵬薬品工業株式会社 ピリミジン化合物又はその塩

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8426428B2 (en) * 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
US9034885B2 (en) * 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
WO2013118817A1 (ja) 2012-02-07 2013-08-15 大鵬薬品工業株式会社 キノリルピロロピリミジン化合物又はその塩
PT3345907T (pt) 2015-09-01 2020-06-23 Taiho Pharmaceutical Co Ltd Compostos de pirazolo[3,4-d]pirimidina ou sais dos mesmos
EP3269370B1 (en) 2016-02-23 2020-01-08 Taiho Pharmaceutical Co., Ltd. Novel condensed pyrimidine compound or salt thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020145374A1 (ja) * 2019-01-11 2020-07-16 大鵬薬品工業株式会社 ピリミジン化合物又はその塩
CN113271950A (zh) * 2019-01-11 2021-08-17 大鹏药品工业株式会社 嘧啶化合物或其盐

Also Published As

Publication number Publication date
JP7495983B2 (ja) 2024-06-05
AU2021309779A1 (en) 2023-02-23
CN116368136A (zh) 2023-06-30
PH12023550119A1 (en) 2024-06-24
JPWO2022014639A1 (enExample) 2022-01-20
BR112023000770A2 (pt) 2023-02-07
MX2023000693A (es) 2023-02-13
US20230285397A1 (en) 2023-09-14
KR20230026451A (ko) 2023-02-24
EP4197538A1 (en) 2023-06-21
KR102873219B1 (ko) 2025-10-17
CA3189460A1 (en) 2022-01-20
WO2022014639A1 (ja) 2022-01-20
AU2021309779B2 (en) 2024-06-27
TW202216152A (zh) 2022-05-01
EP4197538A4 (en) 2024-08-07

Similar Documents

Publication Publication Date Title
CN116368136B (zh) Egfr抑制剂
CN113271950B (zh) 嘧啶化合物或其盐
JP7358491B2 (ja) 新規なヘテロトリシクリック誘導体化合物およびその用途
JP7373664B2 (ja) 腫瘍の治療に使用されるピリミジン化合物を含む組み合わせ
AU2021307245B2 (en) Crystal of pyrimidine compound
RU2787992C1 (ru) Пиримидиновое соединение или его соль
RU2817044C1 (ru) Ингибитор egfr
HK40056369A (en) Pyrimidine compound or salt thereof
HK40090490A (zh) Egfr抑制剂
HK40056369B (zh) 嘧啶化合物或其盐
TWI905228B (zh) 嘧啶化合物之結晶
BR112021013460B1 (pt) Composto pirimidina, composição farmacêutica e agente antitumoral que compreendem o mesmo e usos do dito composto para o tratamento de tumor
BR122024008319A2 (pt) Composto pirimidina, composição farmacêutica e agente antitumoral que compreendem o mesmo e usos do dito composto para o tratamento de tumor
HK40087564A (zh) 嘧啶化合物的结晶

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40090490

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant